Search results
Results from the WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
In August 2020, the U.S. Food and Drug Administration (FDA) became aware of nitrosamine impurities in certain samples of rifampin. [61] The FDA and manufacturers are investigating the origin of these impurities in rifampin, and the agency is developing testing methods for regulators and industry to detect the 1-methyl-4-nitrosopiperazine (MNP ...
The rifamycin group includes the classic rifamycin drugs as well as the rifamycin derivatives rifampicin (or rifampin), rifabutin, rifapentine, rifalazil and rifaximin. Rifamycin, sold under the trade name Aemcolo, is approved in the United States for treatment of travelers' diarrhea in some circumstances. [1] [2] [3]
[1] Side effects are those of the underlying medications. [1] These may include poor coordination, loss of appetite, nausea, joint pain, feeling tired, and numbness. [2] Severe side effects include liver problems. [3] Use in those under the age of 15 may not be appropriate. [3] It is unclear if use in pregnancy is safe for the baby. [3]
Isoniazid/rifampicin, also known as isoniazid/rifampin, is a medication used to treat tuberculosis. [1] It is a fixed dose combination of isoniazid and rifampicin (rifampin). [1] It is used together with other antituberculosis medication. [1] It is taken by mouth. [1] It is on the World Health Organization's List of Essential Medicines. [2]
Rifapentine, sold under the brand name Priftin, is an antibiotic used in the treatment of tuberculosis. [2] In active tuberculosis it is used together with other antituberculosis medications. [2]
[159] [160] According to the WHO fifty one new therapeutic entities - antibiotics (including combinations), are in phase 1–3 clinical trials as of May 2017. [157] Antibiotics targeting multidrug-resistant Gram-positive pathogens remains a high priority. [161] [157] A few antibiotics have received marketing authorization in the last seven years.
[1] His name is associated with the following three medical terms: Fournier's gangrene: gangrene caused by infection of the scrotum and usually associated with diabetes. Although the condition is named after Fournier after he published a series of five cases, [2] it was first described by a physician named Baurienne in 1764. [3]